Treace raises 2026 revenue guidance to $204 mln-$212 mln, down 4% to flat vs 2025
Company now expects 2026 adj EBITDA loss of $3 mln-$5 mln, vs prior $4 mln-$6 mln loss
Treace expects 2026 cash usage to decline about 50% from 2025
Overview
US bunion surgery device maker's Q2 revenue fell 4% yr/yr but beat analyst expectations
Company raised full-year revenue guidance, now expecting a 4% to 0% yr/yr decline
Net loss narrowed and adjusted EBITDA loss improved from a year earlier
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$45.38 mln
$44.02 mln (5 Analysts)
Q2 Loss Per Share
$0.24
Q2 Gross Margin
78.50%
Q2 Gross Profit
$35.61 mln
Result Drivers
SURGEON ADOPTION - Co said accelerating case volumes and market share gains were driven by increased surgeon adoption of its expanded bunion portfolio and new technologies
- Operating expenses fell 8% yr/yr, which co attributed primarily to targeted expense reduction initiatives
NEW PRODUCT LAUNCHES - Co initiated limited market release of SuperBite Compression Screw System and completed first surgical case with HyperPlate XM Dynamic Compression Locking Implant System
TMCI•
